Plasmepsin (digestive vacuole plasmepsin) (PM (commonly abbreviated as PM I, PM II, PM III, PM IV))

Plasmepsins are a family of pepsin-like aspartic proteases present in the digestive vacuole of the malaria parasite Plasmodium falciparum[2][3]. They are critical for the initial steps of hemoglobin degradation, which provides essential amino acids and helps maintain parasite metabolism[2][3][6]. The major digestive vacuole plasmepsins are Plasmepsin I, II, III, and IV, each capable of degrading hemoglobin under acidic conditions typical of the parasite's food vacuole[2][3][6]. Their function is partially redundant with cysteine proteases known as falcipains, and both enzyme families act together to ensure efficient protein catabolism in the parasite[1][3][5]. While structurally targeted drug discovery efforts have centered on plasmepsin inhibition, genetic and biochemical validation suggests that inhibition of plasmepsins alone is not sufficient to completely arrest parasite growth, because of functional redundancy and compensatory nutrient pathways[1][3][5]. Consequently, while still actively studied, plasmepsins alone are not considered ideal single-agent therapeutic targets, though combinations with falcipain inhibition may show improved efficacy[1][3][5][6].

Other names

Plasmepsin IPlasmepsin IIPlasmepsin IIIPlasmepsin IVPM IPM IIPM IIIPM IVDigestive vacuole plasmepsinHemoglobinase (generic, not standard)

Inhibition of protease activity blocks hemoglobin digestion and can kill or slow growth of Plasmodium parasites in erythrocytes[1][3][5]